Premium
Evaluation of plasma tissue factor and tissue factor pathway inhibitor levels in childhood hemangiomas
Author(s) -
Türker Meral,
İrken Gülersu,
Ören Hale,
Yılmaz Şebnem,
Yüksel Faize,
Olgun Nur
Publication year - 2006
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20729
Subject(s) - tissue factor pathway inhibitor , medicine , tissue factor , significant difference , plasma levels , pathology , gastroenterology , endocrinology , coagulation
Background The purpose of the study was to evaluate the plasma levels of tissue factor (TF), an angiogenic marker, and tissue factor pathway inhibitor (TFPI), an antiproliferative protein, in the childhood hemangiomas at proliferative and regressive stages. Procedure The study included 30 patients with hemangiomas and 30 healthy children. Localization, number, stage, type, duration of growth, and complications of the hemangiomas were determined. Venous blood samples from all individuals were collected into citrated tubes and centrifuged. Supernatant plasma was separated, aliquated, and stored at −70°C until samples could be assayed. Plasma levels of TF and TFPI were measured with quantitative ELISA kits. Results Plasma TF and TFPI levels did not show any significant difference between the study and control groups. When plasma TF and TFPI levels of the children in the control group and in the study group who were in proliferative and regressive stage were compared to each other, no statistically significant difference could be detected. Conclusions Plasma TF and TFPI levels of our patients with hemangiomas were not different from healthy children and they did not show any significant difference in proliferative and regressive stages. © 2006 Wiley‐Liss, Inc.